Patients with EGFR -mutated non-small cell lung cancer (NSCLC) have 3 treatment options that can be used in the frontline.
While osimertinib monotherapy is a standard first-line treatment, data have revealed positive findings with the combination of osimertinib plus chemotherapy and amivantamab plus lazertinib.
At the 2025 American Society of Clinical Oncology Annual Meeting, Coral Olazagasti, MD, University of Miami Health System, Miami, Florida, provided perspective on how to guide community oncologists on treatment sequencing.
Dr. Olazagasti told colleague Chinmay Jani, MD, University of Miami Health System, that it’s not a one-size-fits-all approach to treating patients with EGFR -positive NSCLC. She advised that community oncologists have a conversation with their patient and decide on a treatment strategy together based on a patient’s lifestyle and priorities.
“It’s not necessarily to only choose the first-line and think about what you’re going to do in the frontline setting, but to think about the [treatment] journey,” Dr. Olazagasti said.
Shared decision-making should also be used when reviewing treatment toxicities. Although the survival data have been positive, adverse events (AEs) can be a challenge, particularly with the amivantamab and lazertinib combination. Dr. Olazagasti advocated for tailoring therapy to the individual patient after considering AEs.
